Rosacea (Erythematotelangiectatic)
Investigational use for erythematotelangiectatic rosacea; no clinical study of leech therapy was identified.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for rosacea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for rosacea is investigational.
- What evidence exists?
- No clinical study of leech therapy for rosacea was identified in our literature search. Tier C (investigational). No randomized controlled trial was identified. Evidence-based first-line treatments include trigger avoidance, sun protection, topical brimonidine or oxymetazoline for erythema, topical metronidazole or ivermectin for inflammatory lesions, and vascular laser/IPL for telangiectasia.
- Main risks
- Bleeding from bite sites on the face for 6 to 24 hours after detachment
- Bruising and tenderness on visible facial skin for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Hyperpigmentation or permanent small scars on the face at bite sites — cosmetically significant
- Worsening of inflammatory papulopustular lesions in some patients
- Worsening of facial erythema or flushing in the short term
- Trigger of ocular rosacea if leech placed near eyelids
- Delay of evidence-based topical or oral therapy
- Who should not consider this
- Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with anemia
- Patients with active inflammatory rosacea flares with pustules
- Patients with ocular rosacea (involve ophthalmology; do not apply near eye)
- Patients with a tendency to keloid or hypertrophic scarring
- Patients prioritizing cosmetic outcome (visible facial scars possible)
- Patients with phymatous rosacea (laser ablation or surgical management)
- Patients with rosacea fulminans (oral isotretinoin or systemic steroid)
- Patients with darker Fitzpatrick skin types at high PIH risk
- Pregnant patients
- What to ask your clinician
- Have I been evaluated by a dermatologist?
- Have I trialed evidence-based therapies (topical brimonidine/oxymetazoline, metronidazole, ivermectin, vascular laser, IPL)?
- What evidence supports leech therapy for rosacea specifically?
- What is the realistic chance of benefit, and for how long?
- What is the risk of permanent facial scarring or hyperpigmentation?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- Am I a candidate for sub-antimicrobial doxycycline 40 mg modified-release?
- Will leech placement risk worsening my flushing or burning?
- Are leeches from an FDA-registered supplier and used only once?
- When to seek urgent care
- Spreading redness, warmth, pus, or red streaks on the face (facial cellulitis)
- Eye pain, vision change, or eye redness (ocular involvement)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
- Severe sudden facial swelling with fever (rosacea fulminans — emergency)
What this does NOT mean
- This is not FDA-cleared for rosacea.
- With no clinical studies identified, efficacy versus placebo or evidence-based topical and laser therapies is unknown.
- Mechanism rationale (vasoactive peptides) does NOT establish clinical efficacy.
- Facial leech placement carries cosmetic risk — small scars on visible skin are possible.
- Leech therapy is not a substitute for dermatology evaluation and standard topical/laser treatment.
- It does NOT address ocular rosacea or phymatous changes, which require specialty care.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L71.0, L71.1, L71.8, L71.9
- Safety tier
- Low
Evidence Summary
No clinical study of leech therapy for rosacea (controlled trial, case series or case report) was identified in PubMed, Europe PMC, ClinicalTrials.gov, the Baskova and Isakhanyan 2004 monograph, or Russian- and German-language searches. The only items found were an expert-opinion questionnaire in cosmetology (Zabkowska et al. 2022, Cosmetics 9(6):137) and non-peer-reviewed clinic and consumer web pages. Any proposed mechanism (anti-inflammatory salivary peptides, local vascular effects) is speculative and unproven in this condition. Phymatous rosacea in particular would not be expected to respond. Standard treatments (topical brimonidine, oxymetazoline, ivermectin, azelaic acid, oral doxycycline, and vascular laser or intense pulsed light) remain first-line. ASH position: any use of leech therapy for rosacea is investigational and mechanistic only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Ocular rosacea with active blepharitis
- Recent (<6 weeks) facial laser or peel
- Rhinophyma stage requiring surgical management
- Patients with darker Fitzpatrick types at high PIH risk
Related Conditions
Plaque Psoriasis (Localized)
Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Atopic Eczema (Localized Refractory)
Investigational use for localized refractory eczema; evidence is limited to a few small studies without placebo or standard-care controls.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.